药物诱导的自身免疫性肝炎的研究进展

高晓琴; 赵永勋; 任茜; 周永宁

doi:10.3969/j.issn.1001-5256.2017.11.038

药物诱导的自身免疫性肝炎的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.11.038

1. 兰州大学第一医院消化科
2. 兰州大学第一医院胃肠病重点实验室
3. 兰州大学第一医院肿瘤外科

基金项目:

国家科技惠民计划项目(2012GS620101)；甘肃省卫生行业科研管理项目(GWGL2010-17)；中央高校基本科研业务费专项资金项目(lzujbky-2013-157)；

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1549
- HTML全文浏览量: 29
- PDF下载量: 453
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-02
- 出版日期: 2017-11-20

Research advances in drug-induced autoimmune hepatitis

Department of Gastroenterology, The First Affiliated Hospital of Lanzhou University

Research funding:

摘要

摘要: 药物诱导的自身免疫性肝炎是由药物触发自身免疫系统导致的肝损伤,约占药物性肝损伤的6%~22%。目前,药物诱导的自身免疫性肝炎的发病机制尚未完全阐明,亦无特异性的诊断标准,临床诊断困难。重点介绍药物诱导的自身免疫性肝炎的发病情况、危险因素、发病机制、临床特征等方面的研究进展,以增强临床医生对这一特殊类型肝损伤的认识,提高对药物诱导的自身免疫性肝炎的诊断及治疗水平。
- 肝炎,自身免疫性 /
- 肝炎,慢性,药物性 /
- 综述
Abstract: Drug-induced autoimmune hepatitis (DIAIH) refers to liver injury mediated by the autoimmune system activated by drugs and accounts for 6%-22% of drug-induced liver injury.At present, the pathogenesis of DIAIH remains unclear, and there are no specific diagnostic criteria, which causes the difficulties in clinical diagnosis.This article introduces the research advances in the incidence, risk factors, pathogenesis, and clinical features of DIAIH, in order to help clinicians learn more about this special type of liver injury and improve its clinical diagnosis and treatment.
- hepatitis, autoimmune /
- hepatitis, chronic, drug-induced /
- review

HTML全文

参考文献(43)

[1]BJORNSSON ES, BERGMANN OM, BJORNSSON HK, et al.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.

[2]KUZU UB, OZTAS E, TURHAN N, et al.Clinical and histological features of idiosyncratic liver injury:Dilemma in diagnosis of autoimmune hepatitis[J].Hepatol Res, 2016, 46 (4) :277-291.

[3]LICATA A, MAIDA M, CABIBI D, et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis:a retrospective cohort study[J].Dig Liver Dis, 2014, 46 (12) :1116-1120.

[4]BJORNSSON E, TALWALKAR JA, TREEPRASERTSUK S, et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis[J].Hepatology, 2010, 51 (6) :2040-2048.

[5]PARHAM LR, BRILEY LP, LI L, et al.Comprehensive genomewide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07∶01[J].Pharmacogenomics J, 2016, 16 (2) :180-185.

[6]van GERVEN NM, de BOER YS, ZWIERS A, et al.HLA-DRB1*03∶01 and HLA-DRB1*04∶01 modify the presentation and outcome in autoimmune hepatitis type-1[J].Genes Immun, 2015, 16 (4) :247-252.

[7]STEPHENS C, CASTIELLA A, GOMEZ-MORENO EM, et al.Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis:the influence of human leucocyte antigen alleles[J].Pharmacogenet Genomics, 2016, 26 (9) :414.

[8]de BOER YS, KOSINSKI AS, URBAN TJ, et al.Features of autoimmune hepatitis in patients with drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2016, 15 (1) :103.

[9]HISAMOCHI A, KAGE M, IDE T, et al.An analysis of drug induced liver injury, which showed histological findings similar to autoimmune hepatitis[J].J Gastroenterol, 2016, 51 (6) :597-607.

[10]SAKAGUCHI S, SAKAGUCHI N, ASANE M, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) .Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol, 1995, 155 (3) :1151.

[11]TAN Z, QIAN X, JIANG R, et al.IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation[J].J Immunol, 2013, 191 (4) :1835-1844.

[12]CHANG SH, REYNOLDS JM, PAPPU BP, et al.Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E[J].Immunity, 2011, 35 (4) :611-621.

[13]HUANG J, YUAN Q, ZHU H, et al.IL-17C/IL-17RE augments T cell function in autoimmune hepatitis[J].J Immunol, 2016, 198 (2) :669-680.

[14]LONGHI MS, MA Y, GRANT CR, et al.T-regs in autoimmune hepatitis-systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile[J].J Autoimmun, 2013, 41:146-151.

[15]HENINGER AK, THEIL A, WILHELM C, et al.IL-7 abrogates suppressive activity of human CD4+CD25+Fox P3+regulatory Tcells and allows expansion of alloreactive T cells[J].J Immunol, 2012, 189 (12) :5649-5658.

[16]MORIKAWA H, SAKAGUCHI S.Genetic and epigenetic basis of Treg cell development and function:from a Fox P3-centered view to an epigenome-defined view of natural Treg cells[J].Immunol Rev, 2014, 259 (1) :192-205.

[17]SHEVACH EM, THORNTON AM.t Tregs, p Tregs, and i Tregs:similarities and differences[J].Immunol Rev, 2014, 259 (1) :88-102.

[18]PARK MK, PARK JS, PARK EM, et al.Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis[J].Arthritis Rheumatol, 2014, 66 (5) :1195-1207.

[19]FENG H, YIN J, HAN YP, et al.Sustained changes of Treg and Th17cells during interferon-αtherapy in patients with chronic hepatitis B[J].Viral Immunol, 2015, 28 (8) :412-417.

[20]HOOFNAGLE JH, SHERKER AH.Hepatitis C:down but not out[J].Ann Intern Med, 2017, 166 (9) :675.

[21]VUPPALANCHI R, GOULD RJ, WILSON LA, et al.Clinical significance of serum autoantibodies in patients with NAFLD:results from the nonalcoholic steatohepatitis clinical research network[J].Hepatol Int, 2012, 6 (1) :379-385.

[22]SUZUKI A, BRUNT EM, KLEINER DE, et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology, 2011, 54 (3) :931-939.

[23]TAKEDA K, ODA M, OKADA T, et al.Over-the-counter drug induced autoimmune hepatitis[J].Intern Med, 2016, 55 (10) :1293-1297.

[24]LANG ZW.Pathological advances in autoimmune liver disease[J].JClin Hepatol, 2012, 28 (5) :326-331. (in Chinese) 郎振为.自身免疫性肝病的病理学新进展[J].临床肝胆病杂志, 2012, 28 (5) :326-331.

[25]STINE JG, LEWIS JH.Current and future directions in the treatment and prevention of drug-induced liver injury:a systematic review[J].Expert Rev Gastroenterol Hepatol, 2015, 10 (4) :1.

[26]STINE JG, INTAGLIATA N, SHAH NL, et al.Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis[J].Dig Dis Sci, 2015, 60 (4) :1031-1035.

[27]LICATA A, MAIDA M, CABIBI D, et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis:a retrospective cohort study[J].Dig Liver Dis, 2014, 46 (12) :1116-1120.

[28]AIZAWA Y, HOKARI A.Autoimmune hepatitis:current challenges and future prospects[J].Clin Exp Gastroenterol, 2017, 10:9-18.

[29]LIU ZX, KAPLOWITZ N.Immune-mediated drug-induced liver disease[J].Clin Liver Dis, 2002, 6 (3) :755-774.

[30]WEILERNORMANN C, SCHRAMM C.Drug induced liver injury and its relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :747-749.

[31]CZAJA AJ.Drug-induced autoimmune-like hepatitis[J].Dig Dis Sci, 2011, 56 (4) :958-976.

[32]LUCENA MI, MOLOKHIA M, SHEN Y, et al.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles[J].Gastroenterology, 2011, 141 (1) :338-347.

[33]BESSONE F, HERNANDEZ N, SANCHEZ A.The Spanish-latin American DILI network:preliminary results from a collaborative strategic initiative[J].J Hepatol, 2012, 58 (Suppl 1) :s212-s213.

[34]ANDRADE RJ, MEDINA-CALIZ I, STEPHENS C.La hepatotoxicidad recurrente seasocia frecuentemente a manifestaciones de autoinmunidad[J].Gastroenterol Hepatol, 2013, 36:84.

[35]OHMOTO K, YAMAMOTO S.Drug-induced liver injury associated with antinuclear antibodies[J].Scand J Gastroenterol, 2002, 37 (11) :1345-1346.

[36]CRISMALE JF, STUECK A, BANSAL M.Toxin-induced autoimmune hepatitis caused by raw cashew nuts[J].ACG Case Rep J, 2016, 3 (4) :133.

[37]YANG MR, LIU B, ZHANG GS, et al.Bicyclol combined with magnesium isoglycyrrhizinate for drug-induced autoimmune hepatitis[J].J Chin Practical Diagn and Ther, 2017, 31 (3) :278-290. (in Chinese) 杨美荣, 刘斌, 张国顺, 等.双环醇联合异甘草酸镁治疗药物诱导自身免疫性肝炎效果观察[J].中华实用诊断与治疗杂志, 2017, 31 (3) :278-290.

[38]ZHANG GS, SHANG H, GAO BX, et al.Clinical study of isoglycyrrhizinate with thymosinα1 in treatment of drug-induced autoimmune hepatitis[J].Chin J Gastroenterol Hepatol, 2012, 21 (7) :649-651. (in Chinese) 张国顺, 尚华, 高宝霞, 等.异甘草酸镁联合胸腺肽α1治疗药物诱导自身免疫性肝炎的临床研究[J].胃肠病学和肝病学杂志, 2012, 21 (7) :649-651.

[39]YAN ZH, WANG YM, TANG B, et al.Meta-analysis of magnesium isoglycyrrhizinate combined with nucleoside ana-logues in patients with chronic hepatitis B[J].Chin J Hepatol, 2014, 22 (2) :108-112. (in Chinese) 晏泽辉, 王宇明, 汤勃, 等.异甘草酸镁联合核苷类似物治疗慢性乙型肝炎的荟萃分析[J].中华肝脏病杂志, 2014, 22 (2) :108-112.

[40]KLEINER DE, BERMAN D.Pathologic changes in ipilimumabrelated hepatitis in patients with metastatic melanoma[J].Dig Dis Sci, 2012, 57 (8) :2233.

[41]CHMIEL KD, SUAN D, LIDDLE C, et al.Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy[J].J Clin Oncol, 2011, 29 (9) :237-240.

[42]YANG F, WANG Q, JIA J, et al.Autoimmune hepatitis:east meets west.[J].J Gastroenterol Hepatol, 2015, 30 (8) :1230.

[43]ZHANG H, LIU Y, BIAN Z, et al.The critical role of myeloidderived suppressor cells and FXR activation in immune-mediated liver injury[J].Autoimmun, 2014, 53:55-66.

施引文献

资源附件(0)

访问统计